학술논문
A randomized phase II evaluation of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma
Document Type
Article
Author
Source
In Gynecologic Oncology June 2020 157(3):585-592
Subject
Language
ISSN
0090-8258